AbbVie Inc. (NYSE:ABBV) Given Consensus Rating of “Moderate Buy” by Analysts

AbbVie Inc. (NYSE:ABBV) has been given an average recommendation of “Moderate Buy” by the twenty-two ratings firms that are covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $251.00.

Several equities analysts recently commented on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $258.00 target price on shares of AbbVie in a report on Thursday, January 15th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Morgan Stanley lifted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Scotiabank initiated coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company.

AbbVie Stock Up 1.8%

Shares of ABBV stock opened at $231.57 on Monday. The business has a 50-day moving average price of $223.56 and a two-hundred day moving average price of $221.07. AbbVie has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market cap of $409.28 billion, a P/E ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie will post 12.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ABBV. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter worth about $26,000. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter valued at approximately $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the 2nd quarter worth approximately $28,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the 4th quarter worth approximately $28,000. Finally, Westend Capital Management LLC purchased a new position in shares of AbbVie during the fourth quarter valued at approximately $29,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.